Qiming Venture Partners
Qiming leads $52m round for China’s JingChi
Qiming Venture Partners has led a $54 million pre-Series A round for JingChi, a Chinese self-driving technology company, with participation from US-based strategic investor Nvidia GPU Ventures.
China’s 51Job acquires majority stake in VC-backed Lagou
US-listed Chinese recruitment site 51Job has agreed to acquire a 60% stake in industry peer Beijing Lagou Network Technology, which is backed by Qiming Venture Partners and other VC investors, for $119 million.
China's Zai Lab jumps 55% on debut after $150m IPO
Zai Lab, a Chinese drug developer backed by several venture capital investors, gained 55% on its NASDAQ trading debut following a $150 million IPO.
China cloud services provider Abcfintech raises $30m
Abcfintech, a China-based cloud services provider, has raised a combined $30 million through an angel round and Series A round.
China's VC-backed Zai Lab files for US IPO
Zai Lab, a Chinese drug developer backed by several venture capital investors, has filed for a US IPO. The company has yet to indicate how many shares it plans to sell or at what price.
Qiming leads $21m round for Chinese cancer drug developer
China-based cancer drug developer Antengene Corporation has completed a $21 million Series A round of funding led by Qiming Venture Partners.
Qiming leads $20m round for China cancer specialist
Qiming Venture Partners has led a $20 million round for New Horizon Health, a Chinese start-up that develops cancer screening technology, with participation from existing investors Legend Capital and SBCVC.
Qiming’s US healthcare fund backs Harvard spin-out
Qiming US Healthcare Fund, a sector specialist vehicle launched by China’s Qiming Venture Partners, has led a $10 million Series A round for Platelet BioGenesis, a Harvard University spin-out that builds human platelets from stem cells.
Hong Kong tech IPOs: Compromise solution
Hong Kong wants to reinvest itself as a destination for Chinese technology listings with a new board that would be open to companies that are pre-profit and have dual-class share structures. Will it fly?
Deal focus: Chubao targets mass market appeal
Having built its business by licensing mobile software to smart phone manufacturers, China's Chubao has raised $100 million to bankroll a freemium model that will allow it to interact directly with users
China biopharma player gets $25m Series B
CANbridge Life Science, a Beijing-based clinical-stage biopharmaceutical company focused on developing Western drug candidates in China and North Asia, has raised a Series B round worth $25 million.
China mobile communication app Chubao raises $100m
Shanghai-based mobile communication app developer Chubao Technology has completed a $100 million Series D round co-led by CCB International, an investment unit of China Construction Bank, and China PE firm HG Capital.
CDB Capital leads $42m round for China fintech firm Wacai
CDB Capital, the fund management arm of China Development Bank, has led a $42 million round for Wacai, a Chinese finance management mobile app developer.
Qiming leads $17m round for China data storage software developer
Qiming Venture Partners has led a RMB120 million ($17 million) Series B round for XSKY Beijing Data Technology Corporation, a China-based data storage software services provider.
China serviced apartment operator gets $43m
Anxin Apartment, a China-based serviced apartment operator, has raised RMB300 million ($43 million) in a Series B round spread across two tranches.
Tencent leads $34m round for VC-backed cloud player
Tencent Holding has led a RMB235 million ($34 million) funding round for Transwarp Technology, a Chinese big data technology developer backed by a string of venture capital investors.
VCs commit $65m to China vaccine developer CanSino Biologics
SDIC Fund Management, a GP under China’s State Development & Investment Corporation, has led a $65 million round of funding for CanSino Biologics, a China-based vaccine developer.
Dual currency fundraising: Servant of two masters
A resurgence in renminbi fundraising has prompted GPs best known for US dollar funds to enter the local currency market. Addressing conflicts of interest in an increasingly complex industry will prove difficult
China outbound M&A: Time will tell
Restrictions on outbound investment have China’s investor community scrambling to adapt, but devising a proper response depends on future decisions from notoriously opaque regulatory agencies
China healthcare platform Anxin Doctor raises $29m
Beijing-based Anxin Doctor, a mobile app focused on pediatric and women's healthcare, has completed a RMB200 million ($29 million) Series B round of funding across two tranches.
Renminbi fundraising: Policy power
The launch of several huge government-backed funds has skewed renminbi-denominated fundraising in China. What does their arrival mean for valuations and for the nascent independent LP community?
Qiming leads $20m Series A for China biopharma developer
Qiming Venture Partners has led a $20 million Series A round of funding for Chinese drug developer Connect Biopharmaceuticals.
Deal focus: Q&A start-up Xueba to enter the classroom
Chinese education app provider Xueba raises a $100 million Series C round as it looks to monetize its user base through one-to-one tuition and in-classroom services
China VCs lead $100m round for local education app Xueba
China Merchants Capital and Grand Fight Investment have co-led a $100 million Series C round of funding for Xueba, a Chinese education app that helps students understand homework exercises.